Accepted Manuscript

Accepted Date:

Evaluation of thioamides, thiolactams and thioureas as hydrogen sulfide (H_2S) donors for lowering blood pressure

Ewelina Zaorska, Tomasz Hutsch, Marta Gawryś-Kopczyńska, Ryszard Ostaszewski, Marcin Ufnal, Dominik Koszelewski

PII:	\$0045-2068(19)30252-4
DOI:	https://doi.org/10.1016/j.bioorg.2019.102941
Article Number:	102941
Reference:	YBIOO 102941
To appear in:	Bioorganic Chemistry
Received Date:	14 February 2019
Revised Date:	8 April 2019

18 April 2019

<page-header><page-header><page-header><page-header><page-header><page-header>

Please cite this article as: E. Zaorska, T. Hutsch, M. Gawryś-Kopczyńska, R. Ostaszewski, M. Ufnal, D. Koszelewski, Evaluation of thioamides, thiolactams and thioureas as hydrogen sulfide (H₂S) donors for lowering blood pressure, *Bioorganic Chemistry* (2019), doi: https://doi.org/10.1016/j.bioorg.2019.102941

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Evaluation of thioamides, thiolactams and thioureas as hydrogen sulfide (H_2S) donors for lowering blood pressure

Ewelina Zaorska,^[a] Tomasz Hutsch,^[a] Marta Gawryś-Kopczyńska,^[a] Ryszard Ostaszewski,^[b] Marcin Ufnal,*^[a] and Dominik Koszelewski*^[b]

Affiliation and address:

^[a] prof. M. Ufnal, E. Zaorska, M. Gawryś-Kopczyńska, Tomasz Hutsch:
 Department of Experimental Physiology and Pathophysiology, Laboratory of Centre for Preclinical Research,
 Medical University of Warsaw, Pawińskiego 3c, 02-106 Warsaw, Poland,

^[b] dr. D. Koszelewski, prof. R. Ostaszewski: Institute of Organic Chemistry, Polish Academy of Sciences Kasprzaka 44/52, 01-224 Warsaw, Poland

Corresponding authors: dominik.koszelewski@icho.edu.pl, mufnal@wum.edu.pl

Abstract: Hydrogen sulfide (H₂S) is a biologically important gaseous molecule that exhibits promising protective effects against a variety of pathological processes. For example, it was recognized as a blood pressure lowering agent. Aligned with the need for easily modifiable platforms for the H₂S supply, we report here the preparation and the H₂S release kinetics from a series of structurally diversified thioamides, thiolactams and thioureas. Three different thionation methods based on the usage of a phosphorus pentasulfide and Lawesson reagent were applied to prepare the target thioamides and thiolactams. Furthermore, obtained H₂S was determined and compared with NaHS and GYY4137 using two different detection technics i.e.; fluorescence labeling 7-azido-4-methyl-2*H*-chromen-2-one and 5,5`-dithiobis (2-nitrobenzoic acid), sulfhydryl probe, also known as the Ellman's reagent. We have proved that the amount of releasing H₂S from these compounds is controllable through structural modifications. Finally, the present study shows a hypotensive response to an intravenous administration of the developed donors in the anesthetized rats.

Keywords: hydrogen sulfide, thioamides, thiolactams, thiourea, cardiovascular

Introduction

Hydrogen sulfide (H₂S) at high concentrations is an offensive-smelling and toxic gas with a high solubility in water. However, pioneering work of Kimura's group revealed that at very low concentrations H₂S plays a role of biological mediator.^[1] It is believed that H₂S in living organisms is responsible for the regulation of several physiologically relevant processes e.g. vasorelaxation, hormone secretion, apoptosis and multicellular events like neuro modulation or inflammatory responses.[2] Due to this reason a number of H₂S releasing agents have been developed and validated in various biochemical studies.^[3] Among them, those related to H₂S-mediated vasodilator effects have been paid a great attention.^[4] In nature, H₂S is formed during

an anaerobic bacterial digestion of the organic compounds. Moreover, H_2S is produced in the colon by the commensal bacteria by the reduction of alimentary sulfates.^[5] Under the biological conditions hydrogen sulfide is delivered enzymatically in metabolic pathways from L-cysteine by cystathionine β -synthase and cystathionine y-lyase, from D-cysteine via mercaptopyruvate sulfurtransferase (MPST) with D-amino acid oxidase, and from 3-mercaptopyruvate by MPST with cysteine aminotransferase.^[6] Naturally occurred and rich sources of the sulfur-based organic compounds is garlic.^[7] Recent studies suggest that at least some beneficial effects of garlic are due to H₂S production. So far, the best characterized compound from garlic is allicin (diallyl thiosulfinate), which guickly decomposes into several compounds such as diallyl sulfide (DAS), diallyl disulfide (DADS) and diallyl trisulfide (DATS). Such as naturally H₂S donors may be attractive options for in vivo studies due to lack of toxicity, they unveil problems that accompany many synthetic donors.^[8-9] However, there are some relevant limitations to the use of these compounds: no susceptibility to chemical transformations, poor water solubility, creation of various byproducts after H₂S release.^[10] The most common class of H₂S donors employed in biological studies are the inorganic sulfide salts such as sodium hydrosulfide (NaHS) and sodium sulfide (Na₂S). Generally, sulfide salts are considered as a short-lasting H₂S donors as they release H₂S rapidly.^[11-13] Such uncontrollable and fast H₂S release may exert toxic actions in living systems. Moreover, these compounds release H₂S spontaneously already in time of solution preparation. Such H₂S loss from aqueous solutions making substantial problems with precisely controlled H₂S dose administration what finally may affect biological outcome. Additionally the fact that sulfide salts are hygroscopic may be a source of error in calculations the exact H₂S concentration of dose to be applied to the biologic system.^[14-15] Another problem often raised with commercial sulfide salts, especially NaHS is that almost always they contain some amount of undefined impurities.^[16] Due to these inconveniences organic molecules which act as H₂S agents were developed and used. Thus far various types of organic donors like; dithiolthiones, thiobenzamides, thiocarbamates, dithioesters, and thionoesters, which release H₂S via different mechanisms have been reported,^[17] e.g. hydrolysis,^[18] cellular thiol activation,^[19] and photolysis.^[20] The most widely studied and characterized synthetic H₂S donor is GYY4137 (morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate) complex (Figure 1). Although, GYY4137 is a water-soluble derivative of Lawessons reagent (LR), which releases H₂S via hydrolysis, the rate of H₂S generation firmly depends on pH and turn to be very slow at physiological pH.^[21] Recently, we have shown that the amount of the released H₂S from GYY4137 (140 μ M) at pH 7.4 in aqueous solution is <2 μ M /2,3 μ mol /90 min/13 h.^[22] Additionally, the GYY4137 suffers from several other inconveniences. First, it is often prepared as a dichloromethane complex (ratio 3:1), which is residual from crystallization. Dichloromethane is metabolized to carbon oxide which has biological impact similar to H₂S, therefore some effects attributed to GYY4137-derived H₂S may come from CO.^[23] Finally, it is most likely that reported biological effects observed after administration of GYY4137 are not H₂S-dependent but can be caused by GYY4137 itself or products of its metabolism after H₂S release (Zheng et al., 2015).^[24] Despite the number of literature data regarding H₂S donors only a few show the impact on the vascular system provided from the in vivo studies.



Figure 1. GYY4137 dichloromethane complex.

Regardless of the significant progress in the field of H₂S donor chemistry, there is still a lack of compounds that would meet all the requirements for ideal H₂S donor e.g. water-solubility and generation only innocuous (if any/or not at all) byproducts. Last but not least, it should also have well-defined release mechanism. Among of the organic H₂S donors, thio-analogs of amides and urea have long attracted more and more attention due to their practical application as the precursors for the synthesis of various organic compounds.^[25-28] They are also an important class of bioactive molecules in the field of pharmaceutical industry.^[29-34]

The fact that thioacetamide, one of the simplest organosulfur compound release H₂S by hydrolysis has been known for over a century.^[35,36] As so far, multiple methods for thioamide and thiourea derivatives synthesis have been reported, using various reagents and diverse reaction conditions.^[37-44] Encouraged by the studies revealing biological activity of thioamides and thioureas,^[28-33] we envisioned those compounds as a valuable substructures for the design of sufficient H₂S donors. We assumed also that the type of substituents on the nitrogen atom of amino group of target compounds may provide donors with the desired properties in controlled H₂S release. In this work we designed and synthesized the series of thioamides, thiolactames and thioures derivatives. Then, the newly prepared compounds were evaluated for their H₂S-releasing properties using two independent approaches i.e. fluorescence and DTNB methods. Finally, the selected compounds were submitted to experiments aimed to evaluate their hemodynamic effect on normotensive in rats.

Results

The concept of thionation, i.e. the conversion of the carbonyl group into thiocarbonyl by exchange of an oxygen atom for a sulfur atom is the most commonly used procedure for the preparation of organosulfur compounds. This transformation can be carried out with several commercially available reagents.^[45] Among them, a phosphorus pentasulfide (P_4S_{10}) and the 2,4-bis(4-methoxyphenyl)-1,3-dithiaphosphetane 2,4-disulfide, also known as the Lawesson's reagent, are the most popular (Figure 2).^[46-51] Despite the many advantages of using P_4S_{10} as a thionating reagent, LR is the common choice in organic synthesis. As long as a number of reported protocols regarding LR demonstrate the utility of this reagent, only several of them concomitantly highlighted its limitations. The major difficulties of LR application are byproducts derived from the reagent itself, which cannot be removed by any extractive procedure and must be separated by the time consuming chromatographic techniques. Such tedious separation protocol of the desired product from the LR byproducts can be cumbersome or even impossible, what limits the reagent utility.^[52,53]

LR: MeO OMe

Figure 2. Lawesson's reagent (LR).

Regardless of the high popularity of the Lawesson's reagent as a thionating agent there are several reports refining applicability of the phosphorus pentasulfide by the addition of hexamethyldisiloxane (HMDSO). It was shown that supplementation of P_4S_{10} with HMDSO dramatically increases thionation rates. Moreover, the application of P_4S_{10} /HMDSO system requires simple extractive workup to remove derived byproducts from the final reaction mixture. ^[54,55] Due to the lack of generality and potential problems with the product isolation, both LR and P_4S_{10} were engaged in the synthesis of the target thioamides **2** and thiolactams **3** (Scheme 1). A comparative results obtained under different reaction conditions were shown in Table 1.



Scheme 1. Synthesis of thioamides 2a-j and thiolactams 3a-b.

Thioformamide (2a), N-(2-methoxyethyl)methanethioamide (2b) 4-thioformylmorpholine (2c) and Nmethylthioformamide (2d) were provided from the corresponding formamide derivatives $1a_{-j}$ using P_4S_{10} in diethyl ether with the yields ranging from 75-86%,^[56] In addition, the thionation of selected amides **1f-g** was conducted under different conditions using P₄S₁₀ alone, P₄S₁₀/HMDSO system and LR in three different organic solvents; diethyl ether, DCM and THF (Table 1, entries 5-7). In all cases the application of P_4S_{10} /HMDSO or LR provided corresponding thioamides 2f-g with higher yield than with P₄S₁₀ alone what remains in agreement with the literature data.^[57] The reaction of acetamide **1h** with LR gave desired product **2h** in 93% yield within three hours (Table 1, entry 8). The influence of the used solvent on the reaction performance was negligible. As shown in Table 1 the reaction of aromatic amides 1i and 1j (entries 9-10) with LR afforded the corresponding target thioamides 2i and 2j in high yields up to 90%. The impact of the used solvent on the thionation was examined. There was no evident correlation between used medium and thionation efficiency, products 2i and 2j were obtained with comparable yields (Table 1, entries 9-10). Subtly enhanced yields of the amides 2i and 2j in THF may be explained by the higher solubility of the LR reagent in this solvent. Additionally, two different size-chain thiolactams were synthesized (Table 1, entries 11 and 12).^[58] Pyrrolidin-2-tione (3a) and piperidine-2thione (3b) were provided from the corresponding lactams; 2-pyrrolidinone (1k) and 2-piperidinone (1l), using LR reagent in DCM (Scheme 1).

Table 1. Thionation of amides and lactams under various conditions.

Entry	Amide/Lactam	Thionation reagent	Solvent	Т [°С]	Time [h]	Product	Yield [%] ^[a]	log P ^[b]
1	H ₂ NH 1a	P_4S_{10}	Et ₂ O	0→20	3	H ₂ N H 2a	86	-0.33
2	>°∽∽NH H 1b	P_4S_{10}	Et ₂ O	0→20	3	∠0 NHH 2b	75	0.02
3		$P_{4}S_{10}$	Et ₂ O	0→20	3		80	0.81
4	O N H 1d	P_4S_{10}	Et ₂ O	0→20	3	N H 2d	82	0.01
		P_4S_{10}	Et ₂ O	0→20	24		75	
5	$H^{\text{O}}_{\text{H}} \xrightarrow{H}_{\text{H}} H^{\text{H}}_{\text{H}} \xrightarrow{H}_{\text{O}} H^{\text{H}}_{\text{O}}$	P ₄ S ₁₀ /HMDSO	DCM	60	24	$H^{S}_{H} N^{H}_{H} H^{H}_{2e} S^{H}_{S} H^{H}_{S}$	86	0.10
		LR	THF	20	24		87	
	0	P ₄ S ₁₀	Et ₂ O	0→20	24		70	
6		P ₄ S ₁₀ /HMDSO	DCM	60	24	$H \stackrel{S}{}_{H} \stackrel{O}{}_{2f} \stackrel{H}{}_{S} H$	84	-0.25
		LR	THF	20	24		80	
	.0	P ₄ S ₁₀	Et ₂ O	0→20	24		78	
7		P ₄ S ₁₀ /HMDSO	DCM	60	24	$ \begin{array}{c} & H \\ & H \\ & H \\ & H \\ & S \\ & 2g \end{array} $	90	-0.23
		LR	THF	20	24		85	
8	NH ₂ 1h	LR	THF DCM	20	3	S NH ₂ 2h	93 89	-0.26
9		LR	THF	20	24		90	1.76



[a] Isolated yield. [b] Calculated using ChemBioDraw ultimate software.

The desired products were isolated in high yields up to 93% within two hours. The effect of the lactam ring size on the reaction yield was not observed.

Thoughtful screening of the literature regarding potential H_2S agents provides basis that the thiourea could act as a H_2S donor.^[29-34] Therefore, we designed and synthesized a series of compound based on thiourea scaffold (Scheme 2).



Scheme 2. Synthesis of thiourea derivatives from the corresponding isothiocyanates.

The variously substituted thiourea derivatives **4a-e** were obtained by the reaction of corresponding isothiocyanate with appropriate amine or diamine (Scheme 2).^[59-61] Three different commercially available isothiocyanate were used: methyl isothiocyanate, phenyl isothiocyanate and benzyl isothiocyanate. As shown in the Table 2 the reaction of aromatic isothiocyanate with a structurally diversified amines possessing in their structure hydrophilic groups afforded the corresponding thiourea derivatives **4c-e** in high yields up to 87% (Table 2, entry 3). The reactions also proceeded efficiently with both aliphatic and heterocyclic amines. Application of methyl isothiocyanate resulted in the corresponding thiourea derivatives **4a-b** with the yields up to 92% (Table 2, entries 1 and 2). For diamines the appropriate excess of isothiocyanate (2 equiv.) was used (Table 2, entries 2 and 4).

Table 2. Synthesis of thiourea derivatives 4a-e.



5

toluene

[a] Isolated yield. [b] Calculated using ChemBioDraw ultimate sofware.

The solvents such as an acetone, toluene and DCM were used. The reaction performed in DCM using methyl isothiocyanate resulted in higher yield of the corresponding thiourea derivatives **4a** and **4b** than analogous one conducted in toluene or acetone (Table 2, entries 1 and 2). In the case of isothiocyanates with aromatic ring, toluene revealed to be the most suitable solvent (Table 2, entries 3-5). The higher yield may be due to a higher solubility of the used reagents in given solvent. Additionally, we have developed protocol for the synthesis of symmetrically substituted urea derivative **5** (Scheme 3).^[62]

$$O_{\text{DCM, 0°C, rt}}^{\text{NH}_2} \xrightarrow{\text{CSCI}_2, \text{ Et}_3\text{N}} O_{\text{DCM, 0°C, rt}}^{\text{N}} O_{\text{S}}^{\text{N}} O_{\text{S}}$$

Scheme 3. Synthesis of 1,3-bis(2-morpholin-4-ylethyl)thiourea (5).

The 1,3-bis(2-morpholinoethyl)-thiourea (5) was obtained *via* reaction of 2-morpholinoethan-1-amine with thiophosgene in DCM with 85% yield. The structures of all obtained compounds (**2a-j**, **3a-b**, **4a-e** and **5**) were confirmed by ¹H-, ¹³CNMR spectroscopy, mass spectra analysis and elemental analysis (supplementary materials). Spectroscopic data for the known compounds correspond with the published one. Further, we have evaluated the potential H₂S-releasing capability of the synthesized compounds. Initially, we have validated the newly prepared compounds toward H₂S liberation using recently established and commonly used procedure based on DTNB probe also known as Ellman's reagent (5,5`-dithiobis(2-nitrobenzoic acid). In general, DTNB method is used for the determination of the free sulfhydryl group concentration.^[63-65] DTNB assay for 1 mM solutions of H₂S donors was performed at pH 8.0 according to the protocol provided by the manufacturer (supplementary materials). As shown in Table 3 all prepared compounds liberate H₂S. The highest amount of the released H₂S was observed for **2e** and **2h** thio-derivatives (Table 3, entries 5 and 8), while the lowest one was recorded for compounds **2g**, **4d** and **4e** (Table 3, entries 7, 16 and 17).

Entry	Donor	Conc. [µM]
1	2a	254
2	2b	271
3	2c	407
4	2d	335
5	2e	736

Table 3. In vitro H₂S release evaluation from compounds 2a-j, 3a-b, 4a-f and 5 using DTNB probe.^[a]



[a] 10 mM Ellman's Reagent Solution in sodium phosphate buffer (pH 8.0, 50 mM), room temperature, spectra recorded 15 minutes after addition of H_2S donor at 412 nm. For each donors the absorbance was measured at least three times. Background values were subtracted from the sample values.

Since the DTNB operates at basic conditions which does not meet physiological one (pH 7.4) and can affect the amount of the liberaitng H₂S, we turn our attention toward alternative technique which allows us to measure the reactive sulfur species in physiological environment. Fortunately, the rapid progress drives the emergence of the assay for H₂S detection, which possesses the biotarget sensitivity and synthetic convenience. Up to date, a variety of fluorescent probes for tracking the H₂S in biological samples is available.^[66] Due to the fast catabolism and low stability of H₂S we required a probe that would react rapidly and selectively with low levels of hydrogen sulfide and produce a robust fluorescent signal. In addition, the convenient probe should be characterized by the facile synthesis with an efficient and fast protocol for purification. For these reasons a 7azido-4-methyl-2H-chromen-2-one (6) the non-fluorescence derivative of 7-amino-4-methylcoumarin (Scheme 4) have been carefully selected.^[67] It should be emphasized that probe 6 in contrast to DTNB sensor demonstrates high selectivity and sensitivity toward H₂S over other relevant reactive sulfur species in vitro, as well as identified exogenous H₂S in living cells.^[68] The target probe **6** was synthesized in 88% yield from mhydroxyaniline in accordance with the previously described procedure.^[68] As reflecting diverse state-of-the-art OFF/ON fluorescent mechanism, including the release of fluorophore triggered by reduction of an azide to the amine was showed in Scheme 4. In our experiments, 1 mM of each donor was dissolved in a mixed MeCN/sodium phosphate buffer solution (2:8 v/v, pH 7.4) containing probe 6 (1 mM). The changes in the fluorescence emission spectra at 430 nm (λ_{ex} = 365 nm) were recorded for one hour at room temperature.



Scheme 4. Mechanism of H_2S detection for the probe 6.

Finally, the fluorescence signals were converted to H₂S concentrations based on a reference curve obtained with a series of NaHS standard solutions. In each case H₂S concentrations were determined after 15 minutes. In order to evaluate the release properties of H₂S by studied agents, we carried out independent verification of H₂S release profiles from known H₂S donors; NaHS and GYY4137 under the same experimental conditions (Table 4, entries 1 and 2). Alike previously for DTNB assay, also in the fluorescence method with probe 6 all prepared compounds showed H₂S-releasing capabilities. As can be expected the H₂S-release from all tested compounds is lower than for NaHS. In turn amounts of H₂S release from each of studied donors 2a-j, 3ab, 4a-e and 5 were higher than for well recognized GYY4137. For compound 2a, 3b and 5 the highest H₂Sreleasing was observed (Table 4, entries 3, 14 and 20). The compound 2i released the smallest amounts of H₂S, but still on the higher level than GYY 4137 (Table 4, entry 12). All other compounds were similarly found to generate H₂S under studied conditions. Additionally, for arbitrary selected donors 2a, 3b and 5, fluorescence measurements were performed in assay buffer with addition of rat blood plasma (20% v/v). The obtained results were similar to those obtained in buffer alone, what implies that the intracellular environment does not affect H₂S-release capability of selected donors. Differences in the H₂S-realising values can be associated with the solubility of these compounds in an aqueous medium (for compound with the higher value of log P the amount of H_2S released were lower). We assume that hydrophobic properties of a given compounds can reduce the hydrolysis rate of the studied donors and consequently decrease the generation of H₂S. As can be seen the H₂S release data for thioamide 2a and thiourea derivatives 4a-e correspond to those reordered using DTNB sensor. One the other hand the higher values observed in case of using Ellman's reagent may arise from it varied selectivity toward sulfur species.

Table 4. In vitro H_2S release evaluation from compounds 2a-j, 3a-b, 4a-e and 5 determined in fluorometric assay.

Fluorescence method ^[a]			
Entry	Donor	Conc. [µM] ^[b]	
1	NaHS	260	
2	GYY4137	14	
3	2a	228	
4	2b	146	
5	2c	137	



[a] 1 mM of probe **6** in a mixed MeCN/sodium phosphate buffer solution (2:8 v/v, pH 7.4); a room temperature, the fluorescence response was monitored in range time from 1 to 60 minutes after addition of the H_2S donor. For each donors fluorescence intense was measured three times. [b] The H_2S amount determined after 15 min. For calculation were used the mean obtained from three measurements. Background values were subtracted from the sample values.

Cellular nucleophiles play crucial roles in biological systems. The thiols that occur in cells in the large amount and characterized by the strongest potent reactivity are cysteine (Cys) and reduced glutathione (GSH). According to the literature data, release of H₂S from donors based on thioamide structural motif may be modulated by the organic thiols such as reduced glutathione or/and cysteine.^[69-71] Therefore, additional experiments were pursued in the presence of L-cysteine for selected donors **2a**, **2c**, **2e**, **2i**, **2j**, **3a**, **3b** and **4b**. Due to the lack of selectivity of the DTNB method towards thiol groups further measurements with cysteine were carried out with 7-azido-4-methyl-2*H*-chromen-2-one (**6**). Regardless of the literature data regarding selectivity of the used probe **6**, we have validated this compound using two different reactive sulfur species. These studies proved that probe **6** exhibited high selectivity towards H₂S over cysteine and reduced glutathione (GSH) under studied conditions. As shown in Figure 3, cysteine (4 mM) successfully triggered H₂S release, at a relatively higher level for **2e**, **2i**, **2j**, **3a**, **3b** and **4b** donors (Table 5, entries 3-8). While the release of H₂S from **2a** and **2c** in the presence of 4 mM cysteine was lower than observed in the assay buffer alone (Table 5, entries 1-2).

	Fluorescence m	nethod with probe 6 ^[a]
		PBS/L-cysteine [4mM]
Entry	Donor	Conc. [µM] ^[b]
1	2a	128
2	2c	95
3	2e	111
4	2 i	96
5	2j	95
6	3 a	136
7	3b	197
8	4b	123

Table 5. In vitro H₂S release evaluation in the presence of L-Cysteine (4mM) determined in fluorometric assay.

[a] 1 mM of probe **6** in sodium phosphate buffer (pH 7.4), 4 mM L-cysteine, room temperature, the fluorescence response was monitored in a range time from 1 to 60 minutes after addition of the H_2S donor. For each donors the fluorescence intense was measured three times. [b] The H_2S amount was determined after 15 min. For calculation were used the mean obtained from three measurements. Background values were subtracted from the sample values.



Figure 3. Comparison of the H_2S amount released from the selected H_2S donors (1 mM) in the presence of L-cysteine (grey bars) and in the assay buffer alone (black bars).

Obtained results demonstrate the capability of the thioamides, thiolactams and thioureas derivatives to release H₂S in complex biological systems and also show that cysteine is the regulator of this type of donors. The observed differences in H₂S liberation between the results obtained in both used analytical methods can be associated with way of sample processing and conditions of measurements which are substantially different for the used methods. In comparison to fluorescent method, DTNB method requires alkaline conditions (pH 8.0) The above factors can lead to falsely elevated or decreased H₂S amounts in samples and may be the cause of the observed differences in the results obtained.

Haemodynamic effects of investigated H₂S donors.

Mean arterial blood pressure (MABP) and heart rate (HR) were measured at baseline and after intravenous administration of a vehicle and newly synthesized H₂S donors. The compounds 2a, 2c, 2d, 2j, 3a, 4b and 5 were selected as representatives due to their adequate solubility in the vehicle and proved H₂S release at physiological pH (the fluorescence method). Additionally, we conducted experiments in which hemodynamic effects of thiourea were investigated. The impact of selected H₂S donors on MABP and HR in the normotensive rats are shown in Figures 4-8. There were no significant differences in MABP and HR at baseline between the experimental series. The vehicle did not affect MABP and HR. All investigated H₂S donors produced hemodynamic effects, however, there were differences in the onset and the size of the responses. Specifically, the greatest decrease in MABP was present after administration of 2a whereas the lowest drop in MABP was present after administration of 3a. Simultaneously, a significant reduction in the heart rate was observed. It is important to mention that similar effect has not been observed for the parent lactam 2-pyrrolidinon under similar physiological conditions (Supplementary Materials). The H₂S donors 2a, 2c, 2d produced immediate response. In contrast thiourea and the donor 2j produced decrease in MABP 45 min and 30 min after the administration, respectively. In general, decrease in MABP was accompanied by a decrease in HR for H₂S donors 2a, 2c, 2d, 2j and 3a. However, donor 5 produced a decrease in MABP which was associated with an unstable increase in HR.



Figure 4. Change in (**A**) mean arterial blood pressure (MABP, mmHg) and (**B**) heart rate (HR, beats/min) after the intravenous administration of vehicle (20% v/v of DMSO in saline, n=5) or H₂S donors [**2a** (n=5), **2c** (n=5) and **2d** (n=5) at a dose of 0.8 mmol/kg/BW] in normotensive Sprague Dawley rats.

*p<0.05 – vs. baseline, [†]p<0.05 – vehicle vs. **2a** series., v [#]p<0.05 – vehicle vs. **2c** series, [&]p<0.05 – vehicle vs. **2d** series ${}^{\$}$ p<0.05 – **2a** vs. **2c** series, ${}^{\$}$ p<0.05 – **2a** vs. **2c** series, ${}^{\$}$ p<0.05 – **2a** vs. **2d** series.



Figure 5. Change in (**A**) mean arterial blood pressure (MABP, mmHg) and (**B**) heart rate (HR, beats/min) after the intravenous administration of vehicle (20% v/v of DMSO in saline, n=5) or H₂S donor [**3a** (n=5) at a dose of 0.8 mmol/kg/BW] in normotensive Sprague Dawley rats.

*p<0.05 – vs. baseline, [#]p<0.05 – vehicle vs. **3a** series.







Figure 7. Change in (**A**) mean arterial blood pressure (MABP, mmHg) and (**B**) heart rate (HR, beats/min) after the intravenous administration of vehicle (20% v/v of DMSO in saline, n=5) or H_2S donor [**2**j (n=5) at a dose of 0.8 mmol/kg/BW] in normotensive Sprague Dawley rats.

*p<0.05 – vs. baseline, [#]p<0.05 – vehicle vs. **2j** series.





*p<0.05 – vs. baseline, $p^{\#}$ p<0.05 – vehicle vs. **4b** series, p^{\dagger} p<0.05 – vehicle vs. **5** series, $p^{\$}$ p<0.05 – **4b** vs. **5** series.

Conclusions

By preparing and directly comparing thioamide, thiolactam and thiourea donor platforms, we demonstrate access to a wide array of structural motifs that function as controllable hydrolysis-based H₂S donors. The liberating H₂S ability of these compounds was determined and compared with NaHS and GYY4137. Obtained results proved that controllable H₂S release can be achieved by structural modifications of the donors. We also found that thiolactam pyrrolidin-2-thione (**3a**) reduces heart rate with no significant effect on blood pressure in normotensive Sprague Dawley rats. Further studies evaluating mechanisms of the thiolactams action on the circulatory system are needed. Altogether obtained results highlighted the potential of investigated compounds as the H₂S-donors for basic studies and for the rational design of pharmacotherapeutic agents to treat cardiovascular disorders.

Materials and Methods

General methods. All the chemicals were obtained from commercial sources and the solvents were of analytical grade. ¹H- and ¹³CNMR spectra were recorded in CDCl₃, DMSO-d or acetone-d₆. Chemical shifts are expressed in parts per million. The coupling constants (*J*) are given in hertz (Hz). The elemental analyses were performed on CHN Perkin-Elmer 240 apparatus. TLC analyses were done on Kieselgel 60 F_{254} aluminum sheets. Column chromatography was performed on Merck silica gel 60/230-400 mesh. SiliCycle 60 F_{254} silica gel sheets were used for analytical thin layer chromatography (TLC) and visualized by fluorescence quenching under UV

light. Commercial reagents for quantitating sulfhydryl groups by DTNB method were purchased from Thermo Fisher Scientific (Waltham, Mass., USA). Buffer reagents were purchased from Sigma Aldrich (Saint Louis, Mo., USA) and were used without purification. All spectroscopic measurements were performed in 0.1 mM sodium phosphate buffer (pH 7.4) or 0.1 M sodium phosphate buffer (pH 8.0). UV/Vis spectra were recorded at ambient temperature using a U-1900 spectrophotometer (Hitachi, Chiyoda, Tokyo, Japan) and quartz cuvettes. Fluorescence spectra were recorded at 20 °C in quartz cuvettes using a F7000 spectrofluorometer (Hitachi).

General procedure for thionation reaction using P_4S_{10} (Method A). To a cooled (0-5°C) solution of appropriate amide 1 (1.0 mmol) in diethyl ether (3.0 mL) was added tetraphosporus decasulfide (0.25 mmol) in small portions. The reaction mixture was allowed to reach the ambient temperature and stirred for appropriate time. After the completion, the reaction mixture was filtered and concentrated under vacuum. To the resulting mixture was added silica gel, concentrated in vacuum and purified by silica gel column chromatography using hexanes/ethyl acetate as an eluent to give the title compound 2.

N,*N*'-((ethane-1,2-di-yl-bis(oxy))bis(ethane-2,1-diyl))dimethanethio-amide (2f). The reaction was carried out according to the general Method A with *N*,*N*'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))-di-formamide 1f. The compound 2f was obtained with 70% yield (165 mg, 0.7 mmol). ¹H NMR (400 MHz, DMSO) δ 10.11 (br s, 1H), 9.35-9.13 (m, 1H), 3.70-3.63 (m, 2H), 3.58 (t, *J* = 5.2 Hz, 2H), 3.54-3.41 (m, 5H), 3.31 (s, 3H); ¹³C NMR (100 MHz, DMSO) δ 192.07, 189.06, 70.03, 70.02, 70.01, 69.35, 67.72, 67.66, 48.72, 43.29; Element. Anal. calcd. for C₈H₁₆N₂O₂S₂: C: 40.66, H: 6.82, N: 11.85; found C: 40.49, H: 6.75, N: 11.81; HRMS (ESI) calcd for C₈H₁₆N₂O₂S₂Na (M+Na)⁺ 259.0551; found 259.0549.

N-(2-morpholinoethyl)methanethioamide (2g). The reaction was carried out according to the general Method A with *N*-(2-morpholinoethyl)formamide 1g. The compound 2g was obtained with 78% yield (136 mg, 0.78 mmol). ¹H NMR (400 MHz, CDCl₃) δ 10.11 (s, 1H), 9.21 (d, *J* = 6.4 Hz, 1H), 3.55 (q, *J* = 7.8, 6.2 Hz, 2H), 3.30 (s, 6H), 2.71-2.23 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 188.86, 66.98, 66.40, 55.17, 53.30, 38.96; Element. Anal. calcd. for C₇H₁₄N₂OS: C: 48.25, H: 8.10, N: 16.08; found C: 48.05, H: 8.73, N: 15.92; HRMS (ESI) calcd. for C₇H₁₄N₂OSNa (M+Na)⁺ 197.0725; found 197.0722.

General procedure for thionation using P_4S_{10} /HMDSO (Method B). Amide 1 (1.0 mmol), P_4S_{10} (0.25 mmol), DCM (1.0 mL) and HMDSO (1.67 mmol) were combined, refluxed and stirred 24 h. After this time the reaction mixture was cooled to 0°C and aqueous K_2CO_3 solution (1.26 mL of 5.3 M/ mmol of P_4S_{10} taken) was added. Then to the reaction mixture acetone (equal to one-half of the reaction solvent) and water (1 mL/mmol of P_4S_{10} taken) were added. The reaction mixture was stirred vigorously for 30 min at 0°C. After this time water and an extraction solvent were added, the layers were separated, and the organic phase was washed with aqueous solution of K_2CO_3 , water, and brine. The organic extract was dried over MgSO₄ and evaporated, and the crude product was purified by column chromatography using hexanes/ethyl acetate as an eluent to give product **2**.

N,*N*'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))dimethanethio-amide (2f). The reaction was carried out according to the general Method B with *N*,*N*'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))diformamide (1f).

The compound **2f** was obtained with 84% yield (199 mg, 0.84 mmol). 1 H- and 13 CNMR data were similar to those obtained previously.

N-(2-morpholinoethyl)methanethioamide (2g). The reaction was carried out according to the general Method B with *N*-(2-morpholinoethyl)formamide (1g). The compound 2g was obtained with 90% yield (157 mg, 0.9 mmol). ¹H- and ¹³CNMR data were similar to those obtained previously.

General procedure for thionations with LR (Method C). To a THF solution of appropriate amide **1** (1.0 mmol) was added Lawesson's reagent (0.5 mmol) at room temperature and the mixture was stirred for 24 h. To the resulting mixture silica gel was added and concentrated in vacuum. The residue was purified by column chromatography using hexanes/ethyl acetate as an eluent to give product **2**.

N,*N*'-((ethane-1,2-diyl-bis(oxy))bis(ethane-2,1-diyl))dimethanethio-amide (2f). The reaction was carried out according to the general method A with *N*,*N*'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))diformamide (1f). The compound 2f was obtained with 80% yield (189 mg, 0.8 mmol). ¹H- and ¹³CNMR data were similar to those obtained previously.

N-(2-morpholinoethyl)methanethioamide (2g). The reaction was carried out according to the general Method A with *N*-(2-morpholinoethyl)formamide (1g). The compound 2g was obtained with 85% yield (148 mg, 0.85 mmol). 1 H- and 13 CNMR data were similar to those obtained previously.

General procedure for preparation of thiourea derivatives 3. Method D. The phenyl isothiocyanate (135 mg 1.0 mmol) was dissolved in toluene (5 mL) and then appropriate amine or diamine was added (1.0 or 2.0 mmol, respectively). The reaction mixture was stirred for 24 h. The precipitate was collected by filtration, washed with toluene, concentrated in vacuum. The residue was purified by column chromatography using hexanes/ethyl acetate as an eluent to afford **4d**.

1,1'-(azane-di-yl-bis(ethane-2,1-di-yl))bis(3-phenylthiourea) (4d). The reaction was carried out according to the general Method D with 1-(2-aminoethyl)ethane-1,2-diamine. The compound **4d** was obtained with 78% yield (291 mg, 0.78 mmol). ¹H NMR (400 MHz, CDCl₃) δ 8.33 (s, 1H), 7.48-7.19 (m, 10H), 4.06 (s, 1H), 3.90 (d, *J* = 7.4 Hz, 1H), 3.53 (d, *J* = 6.8 Hz, 6H); Element. Anal. calcd. for C₁₈H₂₃N₅S₂: C: 57.88, H: 6.21, N: 18.75; found C: 57.71, H: 6.03, N: 18.57; HRMS (ESI) calcd for C₁₈H₂₃N₅S₂Na (M+Na)⁺ 396.1293; found 396.1291.

General procedure for preparation of thiourea derivatives 3 in DCM. Method E. A solution of appropriate amine or diamine (1.0 or 2.0 mmol, respectively) in dichloromethane (10 mL) was cooled to 0 $^{\circ}$ C followed by the addition of triethylamine (3.0 mmol). Corresponding phenyl isothiocyanate (1.0 mmol) was added to the reaction mixture and stirred at room temperature for 12 h (monitored by TLC for completion). The reaction mixture was washed with water (3 x 10 mL) followed by brine (3 x 10 mL). Organic layer was dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using hexanes/ethyl acetate as an eluent to give **4d**.

1,1'-(azanediylbis(ethane-2,1-diyl))bis(3-phenylthiourea) (4d). The reaction was carried out according to the general Method E with 1-(2-aminoethyl)ethane-1,2-diamine. The compound **4d** was obtained with 75% yield (280 mg, 0.75 mmol).

General procedure for H_2S detection by fluorescence method in sodium phosphate buffer. The solutions of probe 6 (1 mM) and tested H_2S donor (1 mM) were prepared in sodium phosphate buffer at pH 7.4 (20 % CH_3CN). For the assay, appropriate donor was added to test tube / sample cuvette solution containing probe 6. The total volume of the solution being measured was 2000 µL. The final concentration of probe 6 and donor in test tube / sample cuvette were 1 mM. The fluorescence response was monitored over time. Emission spectra were collected between 350 nm and 550 nm. For all measurements, the excitation wavelength was 365 nm. The measurement points covered the time range from 1 to 60 min after addition of donor. For each donors fluorescence intense was measured three times and the results were averaged.

General procedure for H₂S detection by fluorescence method in the presence of cysteine. The solution of probe **6** (1 mM) and tested H₂S donor (1 mM) were prepared in sodium phosphate buffer containing 20% CH₃CN (pH= 7.4). In these experiments appropriate donor (1 mM) was added directly to the test tubes/sample cuvette solution containing probe **6** and cysteine. The final concentration of probe **6** and donor were 1 mM, while concentration of cysteine was 4 mM. The total volume of the solution being measured was 2000 µL. Emission spectra were collected between 350 nm and 550 nm. The fluorescence response of probe **6** was monitored with λ_{ex} =365 nm. The measurement points covered the time range from 1 to 60 min after addition of donor. For each donor fluorescence intense was measured three times and the results were averaged.

General procedure for H₂S detection using the Ellman's test. For each sample to be tested were prepared test tube/sample cuvette containing 50 μ L of Ellman's reagent solution and 2.5 mL of reaction buffer (Ellman's reagent solution and reaction buffer were prepared according to the procedure/ manual attached by Thermo Fisher Scientific (Catalog number: 22582). Then to the separate test tubes/sample cuvette prepared in step 1 was added 250 μ L of donor solution (1 mM) (for reference cuvette was added 250 μ L of reaction buffer, respectively). 1 mM Solution of donor was prepared using reaction buffer as a solvent. Then test tubes/ sample cuvette were mixed and incubated at room temperature for 15 minutes. After this time was measured absorbance of each sample at 412 nm. For each donors absorbance was measured three times and the results were averaged. Concentration of sulfhydryl groups in each samples was calculate from the molar extinction coefficient of the TNB anion (ϵ = 14.150 M⁻¹ cm⁻¹) according to the procedure/manual attached by Thermo Fisher Scientific (Catalog number: 22582).

Animal experiments. The experiments were performed according to Directive 2010/63 EU on the protection of animals used for scientific purposes and approved by the 2nd Local Bioethical Committee in Warsaw (permission number: WAW2/127/2018). The animals were obtained from the Animal Breeding Department of the Medical University of Warsaw and housed in the Central Laboratory of Experimental Animals in group cages with access to standard laboratory chow and water, ad libitum. The rats were maintained in a temperature-and humidity- controlled room with a 12/12-hour light-dark cycle. The studies were performed on male, 18-20-

weeks-old, normotensive Sprague Dawley rats (SD). All measurements were performed under general anaesthesia with urethane (Sigma-Aldrich) given intraperitoneally (IP) at a dose of 1.5 g/kg of body weight (BW). Before the measurements rats were implanted with a venous catheter and an arterial catheter. The arterial catheter was connected to the Biopac MP 150 (Biopac Systems, Goleta, USA) for haemodynamic recordings. The venous catheter was used for administration of investigated compounds.

Reagents/Drugs. The following drugs were used: compound **2a**, **2c**, **2d**, **2j**, **3a**, **4b**, **5** and thiourea used as a H_2S donor. The solution of H_2S donor was prepared in 0.9% saline containing 20% v/v dimethyl sulfoxide (DMSO).

Haemodynamic measurements. The measurements started 60 minutes after the induction of anaesthesia and stabilization of haemodynamic parameters. Arterial blood pressure was recorded 20 min at baseline (before treatment) and 60 min after intravenous infusions of either 0.3 ml of the vehicle (20% v/v of DMSO (dimethyl sulfoxide) in saline (aqueous 0.9% NaCl)) or H_2S donors at a dose of 0.8 mmol/kg BW (n=5).

Data analysis and statistics. The data are expressed as means + SEM (standard error). Mean arterial blood pressure (MABP) and heart rate (HR) were calculated on the arterial blood pressure tracing by AcqKnowledge 4.3.1 Biopac software (Biopac Systems, Goleta, USA). For the evaluation of MABP and HR response within the series, baseline recordings were compared with recordings after administration of evaluated compounds by means of the analysis of variance (ANOVA) for repeated measures. Comparisons between the treatments were performed by ANOVA. If ANOVA showed a significant difference, the post-hoc Tukey's test was performed. A value of two-sided p<0.05 was considered significant. Analyses were conducted using STATISTICA 13.0.

Acknowledgements

This study was supported by The National Science Centre of Poland under grant No 2016/22/E/NZ5/00647.

References

- [1] a) K. Abe, H. Kimura, J. Neurosci. 1996, 16, 1066-1071; b) D. Mancardi, C. Penna, A. Merlino, P. Del Soldato, D. A. Wink, P. Pagliaro, Biochim. Biophysica Acta (BBA) Bioenerg. 2009, 1787, 864-872; c) E. M. Bos, H. van Goor, J. A Joles, M. Whiteman, H. G. D. Leuvenink, Brit. J. Pharmacol. 2015, 172, 1479-1493; d)
 H. Li, Y. Ma, O. Escaffre, T. Ivanciuc, N. Komaravelli, J. P. Kelley, C. Coletta, C. Szabo, B. Rockx, R. P. Garofalo, A. Casola, J. Virol. 2015, 89, 5557-5568.
- [2] a) E. Łowicka, J. Bełtowski, *Pharmacol. Rep.* 2007, *59*, 4-24; b) L. Li, P. K. Moore, *Trends Pharmacol. Sci.* 2008, *29*, 84-90; c) D. J. Elsey, R. C. Fowkes, G. F. Baxter, *Cell Biochem. Funct.* 2010, *28*, 95-106; d) K. Abe, H. Kimura, *J. Neurosci.* 1996, *16*, 1066-1071; e) R. Hosoki, N. Matsuki, H. Kimura, *Biochem. Biophys. Res. Commun.* 1997, *237*, 527-531; f) K. Abe, H. Kimura, *J. Neurosci.* 1996, *16*, 1066-1071; e) R. Hosoki, N. Matsuki, H. Kimura, *Biochem. Biophys. Res. Commun.* 1997, *237*, 527-531; f) K. Abe, H. Kimura, *J. Neurosci.* 1996, *16*, 1066-1071; g) R. Hosoki, N. Matsuki, H. Kimura, *Biochem. Biophys. Res. Commun.* 1997, *237*, 527-531; h) C. D. Russo, G. Tringali, E. Ragazzoni, N. Maggiano, E. Menini, M. Vairano, P. Preziosi, P. J. Navarra, *J. Neuroendocrinol.* 2000, *12*, 225-233; i) G. Yang, R. Wang, *Acta Physiologica Sinica* 2007, *59*, 133-140; j) Y. Kaneko, T. Kimura, S. Taniguchi, M. Souma, Y. Kojima, Y. Kimura, H. Kimura, I. Niki, *FEBS Lett.* 2009, 583, 377-382; k) M.

Okamoto, T. Ishizaki, T. Kimura, *Nitric Oxide* **2015**, *46*, 32-36; I) E. Distrutti, L. Sediari, A. Mencarelli, B. Renga, S. Orlandi, G. Russo, G. Caliendo, V. Santagada, G. Cirino, J. L. Wallace, S. Fiorucci, *J. Pharmacol. Exp. Ther.* **2006**, *319*, 447-458; m) A. Sparatore, E. Perrino, V. Tazzari, D. Giustarini, R. Rossi, G. Rossoni, K. Erdman, H. Schröder, P. Soldato, *Free Rad. Biol. Med.* **2009**, *46*, 586-592; n) R. Zanardo, V. Branaleone, E. Distrutti, S. Fiorucci, G. Crino, J. Wallace, *J. Fed. Am. Soc. Exp. Biol.* **2006**, *20*, 2118-2120.

- [3] a) K. Kashfi, K. R. Olson, *Biochem. Pharmacol.* 2013, *85*, 689-703; b) S. Taniguchi, I. Niki, *J. Pharmacol. Sci.* 2011, 116, 1-5; c) M. W. Warenycia, R. J. Reiffenstein, L. R. Goodwin, F. P. Dieken, *Toxicol. Lett.* 1989, *47*, 221-224; d) L. R. Goodwin, D. Francom, F. P. Dieken, J. D. Taylor, M. W. Warenycia, R. J. Reiffenstein, G. Dowling, *J. Anal. Toxicol.* 1989, *13*, 105-109; e) S. P. Parajuli, S. Choi, J. Lee, Y. D. Kim, C. G. Park, M. Y. Kim, H. II Kim, C. H. Yeum, J. Y. Jun, *Korean J. Physiol. Pharmacol.* 2010, *14*, 83-89; f) L. Li, M. Bhatia, P. Moore, *Curr. Opin. Pharmacol.* 2006, *6*, 125-129; g) H. Pae, Y. Lee, J. Eun-Kyeong, H. Chung, *Arch. Pharm. Res.* 2009, *32*, 1155-1162; h) R. Banerjee, *Curr. Opin. Chem. Biol.* 2017, *37*, 115-121; i) T. Roger, F. Raynaud, F. Bouillaud, C. Ransy, S. Simonet, C. Crespo, M.-. Bourguignon, N. Villeneuve, J.-P. Vilaine, I. Artaud, E. Galardon, *ChemBioChem* 2013, *14*, 2268-2271.
- [4] a) M. Ali, C. Ping, Y. Mok, L. Ling, M. Whiteman, M. Bhatia, P. K. Moore, *Brit. J. Pharmacol.* 2006, 149, 625-634, b) Y. Cheng, J. Nidisang, G. Tang, K. Cao, R. Wang, *Am. J. Physiol., Heart Circul. Physiol.* 2004, 287, H2316-H2323; c) C. Coletta, A. Papapetropoulos, K. Erdelyi, G. Olah, K. Modis, P. Panopoulos, A. Asimakopoulou, D. Gero, I. Sharina, E. Martin, C. Szabo, *Proc. Natl. Acad. Sci. USA* 2012, 23, 801-807; d) M. Bhatia, Life 2005, *57*, 603-606; e) J. Du, Y. Hui, Y. Cheung, G. Ben, H. Jiang, X. Chen, C. Tang, *Heart Vessels* 2004, *19*, 75-80; f) B. Geng, J. Yang, Y. Qi, J. Zhao, Y. Pang, J. Du, C. H. Tang, *Biochem. Biophys. Res. Comm.* 2004a, *313*, 362-368; g) G. Tang, L. Wu, W. Liang, R. Wang, *Am. Soc. Pharmacol. Exp. Therapeut.* 2005, *69*, 1757-1764;
- [5] a) S. Fiorucci, E. Distrutti, G. Cirino, J.L. Wallace, *Gastroenterology* 2006, 131, 259-271; b) D. R. Linden, *Antioxid. Redox Signal.* 2014, 10, 818-830; c) L. Tomasova, L. Dobrowolski, H. Jurkowska, M. Wrobel, T. Huc, K. Ondrias, R. Ostaszewski, M. Ufnal, *Nitric Oxide* 2016, 60, 50-58.
- [6] a) K. N. Maclean, J. P. Kraus in Signal transduction and the gasotransmitters (Eds.: R. Wang), New Jersey: Humana Press; 2004, pp. 275-292; b) H. Kimura, Amino Acids 2011, 41, 113-121; c) N. Shibuya, M. Tanaka, M. Yoshida, Y. Ogasawara, T. Togawa, K. Ishii, H. Kimura, Antioxid Redox Signal. 2009, 11, 703-714; d) N. Nagahara, T. Ito, H. Kitamura, T. Nishino, Histochem Cell. Biol. 1998, 110, 243-250; e) J. Bełtowski, D. Tokarzewska, Biomed. Rev. 2010, 20, 7-15; f) T. Chiku, D. Padovani, W. Zhu, S. Singh, V. Vitvitsky, R. Banerjee, J. Biol. Chem. 2009, 284, 11601-1612; g) N. Shibuya, Y. Mikami, Y. Kimura, N. Nagahara, H. Kimura, J. Biochem. 2009, 146, 623-626; h) S. E. Bearden, R. S. Beard, J. C. Pfau, Am. J. Physiol. Heart Circul. Physiol. 2010, 299, H1568-H1576.
- [7] P. M. Kris-Etherton, K. D. Hecker, A. Bonanome, S. M. Coval, A. E. Binkoski, K. F. Hilpert, A. E. Griel, T. D. Etherton, Am. J. Med. 2002, 113, 71-88.
- [8] G. A. Benavides, G. L. Squadrito, R. W. Mills, H. D. Patel, T. S. Isbell, R. P. Patel, V. M. Darley-Usmar, J. E. Doeller, D. W. Kraus, *Proc. Natl. Acad. Sci. U.S.A.* 2007, 104, 17977-17982.
- [9] C. Jacob, A. Anwar, T. Burkholz, Planta Med. 2008, 74, 1580-1592.

- [10] a) H. Amagase, J. Nutr. 2006, 136, 716S; b) Y. Zhao, T. D. Biggs, M. Xian, Chem. Commun. 2014, 50, 11788-11805.
- [11] a) E. R. DeLeon, G. F. Stoy, K. R. Olson, *Anal. Biochem.* 2012, *421*, 203; b) D. Yoo, R. C. Jupiter, E. A. Pankey,
 V. G. Reddy, J. A. Edward, K. W. Swan, T. C. Peak, R. Mostany, P. J. Kadowitz, *Am. J. Physiol. Heart. Circ. Physiol.* 2015, *309*, H605-H614.
- [12] R. C. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, J. L. Wallace, FASEB J. 2006, 20, 2118-2120.
- [13] W. M. Zhao, J. Zhang, Y. J. Lu, R. Wang, EMBO J. 2001, 20, 6008-6016.
- [14] L. Liu, H. Liu, D. Sun, W. Qiao, Y. Qi, H. Sun, C. Yan, Circ. J. 2012, 76, 1012-1019.
- [15] J. W. Calvert, M. Elston, C. K. Nicholson, S. Gundewar, S. Jha, J. W. Elrod, A. Ramachandran, D. J. Lefer, *Circulation* 2010, 122, 11-19.
- [16] R. Greiner, Z. Palinkas, K. Basell, D. Becher, H. Antelmann, P. Nagy, T. P. Dick, Antioxid. Redox Signaling.2013, 19, 1749-1765.
- [17] a) C. R. Powell, K. M. Dillon, J. B. Matson, *Biochem. Pharm.* 2018, *149*, 110-123; b) C. Szabo, A. Papapetropoulos, *Pharmacol. Rev.* 2017, *69*, 497-564; c) C. Yang, L. Chen, S. Xu, J. J. Day, X. Li, M. Xian, *Front. Pharmacol.* 2017, *8*, 664; d) M. M. Cerda, T. D. Newton, Y. Zhao, B. K. Collins, C. H. Hendon, M. D. Pluth, *Chem. Sci.* 2019, *10*, 1773-1779; e) N. Lougiakis, A. Papapetropoulos, E. Gikas, S. Toumpas, P. Efentakis, R. Wedmann, A. Zoga, Z. Zhou, E. K. Iliodromitis, A.-L. Skaltsounis, M. R. Filipovic, N. Pouli, P. Marakos, I. Andreadou, *J. Med. Chem.* 2016, *59*, 1776-1790; f) S. D. Zanatta, B. Jarrott, S. J. Williams, *Aust. J. Chem.* 2010, *63*, 946-957; g) W. Yin, L. Lan, Z. Huang, J. Ji, J. Fang, X. Wang, H. Ji, S. Peng, J. Xu, Y. Zhang, *Eur. J. Med. Chem.* 2016, *115*, 369-380; h) Y. Zheng, B. Yu, K. Ji, Z. Pan, V. Chittavong, B. Wang, *Angew. Chem. Int. Ed.* 2016, *55*, 4514-4518; i) Y. Zhao, A. K. Steiger, M. D. Pluth, *Chem. Commun.* 2018, *54*, 4951-4954; j) Y. Zhao, H. A. Henthorn, M. D. Pluth, *J. Am. Chem. Soc.* 2017, *139*, 16365-16376; k) A. K Steiger, S. Pardue, C. G. Kevil, M. D Pluth, *J. Am. Chem. Soc.* 2016, *138*, 7256-7259; l) A. K. Steiger, Y. Yang, M. Royzen, M. D. Pluth, *Chem. Commun.* 2017, *53*, 1378-1380; m) M. M. Cerda, Y. Zhao, M. D. Pluth, *J. Am. Chem. Soc.* 2018, *140*, 12574–12579.
- [18] a) C. J. Gargallo, A. Lanas, J. Dig. Dis. 2013, 14, 55; b) A. Sparetore, G. Santus, D. Giustarini, R. Rossi, P. Del Soldato, Expert Rev. Clin. Pharmacol. 2011, 4, 109-121; c) J. L. Chan, J. L. Wallace, Am. J. Physiol. 2013, 305, G467-G473.
- [19] a) Y. Zhao, H. Wang, M. Xian, J. Am. Chem. Soc. 2011, 133, 15; b) Y. Zhao, S. Bhushan, C. Yang, H. Otsuka, J. D. Stein, A. Pacheco, B. Peng, N. O. Devarie-Baez, H. C. Aguilar, D. J. Lefer, M. Xian, ACS Chem. Biol. 2013, 8, 1283-1290.
- [20] a) Z. M. Voronkov, L. Shagun, L. Ermolyuk, L. Timokhina, J. Sulfur Chem. 2004, 25, 131; b) Z. M. Lukeman, J.
 C. Scaiano, J. Am. Chem. Soc. 2005, 127, 7698; c) Z. N. Fukushima, N. Ieda, K. Sasakura, T. Nagano, K.
 Hanaoka, T. Suzuki, N. Miyata, H. Nakagawa, Chem. Commun. 2014, 50, 587-589.
- [21] L. Li, M. Whiteman, Y.Y. Guan, K.L. Neo, Y. Cheng, S.W. Lee, Y. Zhao, Circulation 2008, 117, 2351-2360.
- [22] A. Drapala, D. Koszelewski, L. Tomasova, R. Ostaszewski, M. Grman, K. Ondrias, M. Ufnal, Acta Biochim. Pol. 2017, 64, 561–566.

- [23] P.K. Moore, M. Whiteman, Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Springer 2015.
- [24] Y. Zheng, X. Ji, K. Ji, B. Wang, Acta Pharm. Sin. B. 2015, 5, 367-377.
- [25] a) P. Reynaud, Y. El Hamad, C. Davrinche, E. Nguyen-Tri-Xuong, G. Tran, G, P. Rinjard, J. Heterocycl. Chem. **1992**, 29, 991-993; b) E. Barresi, G. Nesi, V. Citi, E. Piragine, I. Piano, S. Taliani, F. Da Settimo, S. Rapposelli, L. Testai, M. C. Breschi, C. Gargini, V. Calderone, A. Martelli, J. Med. Chem. **2017**, 60, 7512-7523.
- [26] I. Kraemer, W. Schunack, Arch. Pharm. (Weinheim, Ger.) 1986, 319, 1091-1098.
- [27] B.K. Bhattacharya, H. H. Singh, L. D. S. Yadav, G. Hoornaert, Acta Chim. Acad. Sci. Hung. 1982, 110, 133-144.
- [28] G. F. Meijs, E. Rizzardo, T. P. T. Le, Y. Chen, *Makromol. Chem.* **1992**, *193*, 369-378.
- [29] a) D. B. Sherman, A. F. Spatola, W. S. Wire, T. F. Burks, T. M. D. Nguyen, P. W. Schiller, *Biochem. Biophys. Res. Commun.* **1982**, *162*, 1126-1132; b) W. Tan, J. Wei, X. Jiang, *Org. Lett.* **2017**, *19*, 2166-2169; c) A. Shakeel, A. A. Altaf, A. M. Qures, A. Badshah, *J. Drug Design Med. Chem.* **2016**, *2*, 10-20; d) D. C. Schroeder, *Chem. Rev.* **1955**, *55*, 181-228; e) R. Grzywa, Ł. Winiarski, M. Psurski, A. Rudnicka, J. Wietrzyk, T. Gajda, J. Oleksyszyn, *Bioorg. Med. Chem. Lett.* **2016**, *26*, 667-671; f) T. Murai, *Top Curr. Chem.* **2005**, *251*, 247-272; g) R. N. Hurd, G. DeLaMater, *Chem. Rev.* **1981**, *61*, 45-86; h) T. S. Jagodzinski, *Chem. Rev.* **2003**, *103*, 197-228; i) P. A. Bartlett, K. L. Spear, N. E. Jacobsen, *Biochemistry* **1982**, *21*, 1608-1611; j) M. D. Bond, B. Holmquist, B. L. Vallee, *J. Inorg. Biochem.* **1986**, *28*, 97-105; k) K. L. Yu, A. F. Torri, G. Luo, C. Cianci, K. Grant-Young, S. Danetz, N. A. Meanwell, *Bioorg. Med. Chem. Lett.* **2006**, *14*, 7146-7153; m) M. K. Gannon, J. J. Holt, S. M. Bennett, B. R. Wetzel, T. W. Loo, M. C. Bartlett, T. J. Raub, *J. Med. Chem.* **2009**, *52*, 3328-3341; n) E. J. Petersson, J. M. Goldberg, R. F. Wissner, *Phy. Chem. Chem. Phys.* **2014**, *16*, 6827-6837.
- [30] a) A. Albert, H. Knecht, E. Andersen, V. Hungerford, M. H. Schreier, C. Papageorgiou, *Bioorg. Med. Chem.* **1988**, *8*, 2203-2205; b) E. Rodríguez-Fernández, J. L. Manzano, J. J. Benito, R. Hermosa, E. Monte, J. J. Criado, *J. Inorg. Biochem.* **2005**, *99*, 1558-1572; c) O. J. D'Cruz, F. M. Uckun, *Curr. HIV Res.* **2006**, *4*, 329-345; d) D. Manna, G. Roy, G. Mugesh, *Acc. Chem. Res.* **2013**, *46*, 2706-2715; e) M. Weiss, R. Buhl, M. Medve, E. M. Schneider, *Crit. Care Med.* **1997**, *25*, 128-134; f) L. Harper, L. Chin, J. Daykin, A. Allahabadia, J. Heward, S. C. Gough, C. O. Savage, J. A. Franklyn, *Clin. Endocrinol.* **2004**, *60*, 671-675; g) I. V. Van Daele, H. Munier-Lehmann, M. Froeyen, J. Balzarini, S.V. Van Calenbergh, *J. Med. Chem.* **2007**, *50*, 5281-5292; h)
 Y. Touati-Jallabe, E. Bojnik, B. Legrand, E. Mauchauffée, N. N. Chung, P. W. Schiller, S. Benyhe, M. C. Averlant-Petit, J. Martinez, J. F. Hernandez, *J. Med. Chem.* **2013**, *56*, 5964-5973; i) L. Y. Ma, Y. C. Zheng, S. Q. Wang, B. Wang, Z. R. Wang, L. P. Pang, M. Zhang, J. W. Wang, L. Ding, J. Li, C. Wang, B. Hu, Y. Liu, X. D. Zhang, J. J. Wang, W. Zhao, H. M. Liu, J. *Med. Chem.* **2015**, *58*, 1705-1716.
- [31] a) P. Jeschke, A. Harder, W. Etzel, W. Dau, G. Thielking, G. Bonse, K. Linuma, *Pest Manag. Sci.* 2001, *57*, 1000-1006; b) T. Lincke, S. Behnken, K. Ishida, M. Roth, C. Hertweck, *Angew. Chem.* 2010, *122*, 2055-2057; c) P. Angehrn, E. Goetschi, H. Gmuender, P. Hebeisen, M. Hennig, B. Kuhn, T. Luebbers, P. Reindl, F. Ricklin, A. Schmitt-Hoffmann, *J. Med. Chem.* 2011, *54*, 2207-2024; d) A. Bach, J. N. N. Eildal, N. Stuhr-Hansen, R. Deeskamp, M. Gottschalk, S. W. Pedersen, A. S. Kristensen, K. Strømgaard, *J. Med. Chem.* 2011, *54*, 1333-1346.

- [32] M. H. Cynamon, R. Gimi, F. Gyenes, C. A. Sharpe, K. E. Bergmann, H.J. Han, L. B. Gregor, R. Rapolu, G. Luciano, T. Welch, *J. Med. Chem.* **1995**, *38*, 3902-3907.
- [33] T. E Renau, M. S. Ludwig, J. C. Drach, L. B. Townsend, Bioorg. Med. Chem. Lett. 1992, 2, 1755-1760.
- [34] a) A. S. Mehanna, J. D. Belani, C. J. Kelley, L. A. Pallansc, *Med. Chem.* 2007, *3*, 513-519; b) S. Banala, R. D. Süssmuth, *ChemBioChem* 2010, *11*, 1335-1337.
- [35] L. Lehrman, P. Schneider, J. Chem. Educ. 1955, 32, 474-475.
- [36] X. Wang, B. Wang, Q. Huang, B. Zhang, Z. Hua, Zhonghua Yi Xue Za Zhi 2015, 95, 3176-3179.
- [37] a) M. R. Maddani, K. R. Prabhu, J. Org. Chem. 2010, 75, 2327-2332; b) H. Miyabe, Y. Takemoto, Bull. Chem. Soc. Japan. 2008, 81, 785-795; c) W. Du, D. P. Curran, Org. Lett. 2003, 5, 1765-1768.
- [38] K. A. Mahammed, V. P. Jayashankar, N. Premsai Rai, K. Mohana Raju, P. N. Arunachalam, Synlett 2009, 14, 2338-2340.
- [39] M. L. Boys, V. L. Downs, Synth. Commun. 2006, 36, 295-298.
- [40] T. Kanbara, K. Okamoto, T. Yamamoto, Synlett 2007, 2687-2690.
- [41] C. K. Khatri, A. S. Mali, G. U. Chaturbhuj, Monatsh. Chem. 2017, 148, 1463-1468.
- [42] a) A. Manaka, M. Sato, Synth. Commun. 2005, 35, 761-764; b) Z. D. Wang, G. Feng, M. G. Garcia, T. Wang, Eur. J. Org. Chem. 2018, 598-604.
- [43] S. Ray, A. Bhaumik, A. Dutta, R. J. Butcher, C. Mukhopadhyay, Tetrahedron Lett. 2013, 54, 2164-2170.
- [44] Z. Yin, B. Zheng, J. Sulfur Chem. 2013, 34, 527-531.
- [45] a) T. Ozturk, E. Ertas, O. Mert, Chem. Rev. 2010, 110, 3419-3478; b) Y. A. Tayade, A. D. Jangale, D. S. Dalal, Chem. Select 2018, 3, 8895-8900.
- [46] Z. Kaleta, G. Tarkanyi, A. Gormory, F. Kalman, T. Nagy, T. Soos, Org. Lett. 2006, 8, 1093-1095.
- [47] U. Pathak, L. Pandey, S. Mathur, M. Suryanarayana, Synthesis 2011, 44, 377-379.
- [48] C.H. Yang, G-J. Li, C-J.Gong, Y-M. Li, Tetrahedron 2015, 71, 637-642.
- [49] H. Z. Lecher, R. A. Greenwood, K. C. Whitehouse, T. H. Chao, J. Am. Chem. Soc. 1956, 78, 5018-5022.
- [50] S. Scheibye, J. Kristensen, S.O. Lawesson, Tetrahedron 1979, 35, 1339-1343.
- [51] J. Perregaard, S. Scheibye, H. J. Meyer, I. Thomsen, S.O. Lawesson, Bull. Soc. Chim. Belg. 1977, 86, 679-691
- [52] T. J. Curphey, J. Org. Chem. 2002, 67, 6461-6473
- [53] I. Thomsen, K. Clausen, S. Scheibye, S. O. Lawesson, Org. Synth. 1984, 62, 158-164.
- [54] T. J. Curphey, Tetrahedron Lett. 2002, 43, 371-373.
- [55] T. J. Curphey, *Tetrahedron Lett.* **2000**, *41*, 9963-9966.
- [56] B. Narayana, K.K.Vijaya Raj, B.V. Ashalatha, N. Suchetha Kumari, B.K. Sarojini, European Journal of Medicinal Chemistry 2004, 39, 867-872.
- [55] B. Kaboudin, L. Malekzadeh, Synlett 2011, 19, 2807-2810.
- [58] F. Shibahara, R. Sugiura, T. Murai, Org. Lett. 2009, 11, 3064-3067.
- [59] M. Sarkis, D.-N. Tran, M. C.D. Lang, C. Garbay, E. Braud, Synlett, 2014, 25, 1257-1262.
- [60] M. Urbano, M. Guerrero S. Velaparthi, M. Crisp, P. Chase, P. Hodder, M.T. Schaeffer, S. Brown, H. Rosen,
 E. Roberts, *Bioorg Med Chem Lett.* 2011, 21, 6739-6745.

- [61] Y. He, L. Zhang, X. Liu, X. Li, M. Zheng, H. Li, K. Yu, K. Chen, X. Shen, H. Jiang, H. Liu, J. Med. Chem. 2009, 52, 2465-2481.
- [62] Y. Hagooly, S. Rozen, J. Org. Chem. 2008, 73, 6780-6783.
- [63] A. S. Nashet, D.T. Osuga, R.E. Feeney, Anal. Biochem. 1977, 79, 394-405.
- [64] G. L. Ellman, Arch. Biochem. Biophys. 1959, 82, 70-77.
- [65] T. Gura, Nat. Med. 2008, 14, 706-709.
- [66] a) H. Peng, Y. Cheng, C. Dai, A. L. King, B. L. Predmore, D. J. Lefer, B. Wang, *Angew. Chem.Int. Ed.* 2011, *50*, 9672-9675; b) R. Wang, Z. Li, C. Zhang, Y. Li, G. Xu, Q.-Z. Zhang, L.-Y. Li, L. Yi, Z. Xi, *ChemBioChem* 2016, *17*, 962-968 c) R. Kawagoe, I. Takashima, K. Usui, A. Kanegae, Y. Ozawa, A. Ojida, *ChemBioChem* 2015, *16*, 1608-1615.
- [67] a) J. P. Goddard, J.L. Reymond, *Trends Biotechnol.* 2004, 22, 363-370; b) H. A. Henthorn, M. D. Pluth, J. Am. Chem. Soc. 2015, 137, 15330-15336.
- [68] a) B. Chen, W. Li, C. Lv, M. Zhao, H. Jin, H. Jin, J. Du, L. Zhang, X. Tang, *Analyst* 2013, *138*, 946–951; b) Z.
 Wu, Z. Li, L. Yang, J. Han, S. Han, *Chem. Commun.* 2012, *48*, 10120-10122.
- [69] A. Martelli, L. Testai, V. Citi, A. Marino, I. Pugliesi, E. Barresi, G. Nesi, S. Rapposelli, S. Taliani, F. Da Settimo, M. C. Breschi, V. Calderone, ACS Med. Chem. Lett. 2013, 4, 904-908.
- [70] Y. Zhao, H. Wang, M. Xian, J. Am. Chem. Soc. 2011, 133, 15-17.
- [71] Y. Zhao, S. Bhushan, C. Yang, H. Otsuka, J. D. Stein, A. Pacheco, B. Peng, N. O. Devarie-Baez, H. C. Aguilar, D. J. Lefer, M. Xian, ACS Chem. Biol. 2013, 8, 1283-1290.

Highlights:

Thioamides, thiolactams and thioureas (TTT) may serve as hydrogen sulfide donors.

Hydrogen sulfide release rate is controllable via structural modifications of TTT.

TTT lower arterial blood pressure in rats.

Graphical abstract:

